In recent years, preclinical studies have proposed selective and non-selective MCP-1 antagonists as effective therapeutic agents for a range of inflammatory diseases; however, its therapeutic potential against tumour progression has less evidence. The gene discussed is CCL2; the disease is neoplasm.